Navigation Links
Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
Date:4/21/2008

Prime Therapeutics to present findings at AMCP Conference in April

ST. PAUL, Minn., April 21 /PRNewswire/ -- Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, today announced the results of its study, "Association Between Tumor Necrosis Factor (TNF) Blocker Out-of-Pocket (OOP) Expense and Member Decline to Fill Rate". The study assessed the association between decline-to-fill rates as they relate to out-of-pocket expense for members initiating TNF-blocker therapy for the treatment of inflammatory conditions such as rheumatoid arthritis. The use of TNF blocker agents to treat rheumatoid arthritis has been increasing among the aging U.S. population and treatment for the disease is becoming more and more costly.(1)

Because of Prime's close working relationship with many large health plans, Prime is uniquely positioned to analyze both pharmaceutical and medical data to closely monitor drug safety, effectiveness, costs and prescribing practices. Through the evaluation of pharmacy claims of 4.4 million members from four major Blue Cross and Blue Shield Plans between July 2006 and June 2007, Prime was able to determine that members with an out-of-pocket cost greater than $250 were 4.6 times more likely to decline to fill their initial TNF-blocker medication.

In determining this, Prime found that more than six of seven members initiating TNF-blocker therapy had a per-claim, out-of-pocket expense of $100 or less with a low decline to fill rate of one in 50. The study also found that this decline to fill rate increased to at least one out of every 10 members when the out-of-pocket expense was $251 to $500 and grew to one out of every 5 when members paid the entire cost of greater than $1000. Members generally need to pay approximately $250 when they have a 20% coinsurance pharmacy benefit and they would have to pay the entire cost early in the year when their pharmacy benefit is a consumer directed healthcare product. '/>"/>

SOURCE Prime Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Final Cut Pro X plugin developers have announced a new ... , “ProBlue 5k is a compilation of anamorphic flares that ... Christina Austin, CEO of Pixel Film Studios. “Blurring the line ... changer.” , ProBlue 5k is the ultimate Ultra High Definition ... footage compilation of over 100 anamorphic flares can be applied ...
(Date:9/17/2014)... Las Vegas, NV (PRWEB) September 17, 2014 ... by Dr. Dan Ritchie and Dr. Cody Sipe that is ... quality of life and longevity has caught the attention of ... ask most people in their 50s, 60s, or even 70s ... quality of life on a day-to-day basis, they would probably ...
(Date:9/17/2014)... the ends of chromosomes could hold the key to a ... skin cancer according to new research from the University ... new genetic risk factor for melanoma. , It is well ... of those most at risk of developing melanoma. For example, ... they burn more easily. , It now appears that another ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of Discovery ... would be beneficial in this [MDL].” Accordingly, the court ... end of December,” the order further provides, “the court ... , “The plain import of this order is ... to be discussed as these cases progress toward trial,” ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2
... SAGE Launch Clinical Psychological Science ,Association for Psychological ... Angeles, CA (April 23, 2012) The Association for ... Clinical Psychological Science , a new peer-reviewed journal focused ... venue for cutting-edge research across a wide range of ...
... Guy, M.D., professor of ophthalmology at Bascom Palmer Eye ... Medicine, has pioneered a novel technological treatment for Leber ... causes rapid, permanent, and bilateral loss of vision in ... Genetic mutations in the mitochondria (part of the ...
... 23 (HealthDay News) -- Teen drivers and passengers are more likely ... belt laws, often promoted as "click it or ticket" laws, a ... and ticket drivers solely for not wearing a seat belt. Under ... are stopped for other reasons, such as speeding. Primary seat ...
... The Global Cardiovascular Disease Taskforce called on the 11,000 ... cardiovascular disease (CVD) community at large, to support the ... disease (NCD) mortality by 25 per cent by 2025. ... from the world,s largest CVD organizations including the American ...
... Hispanic lung cancer patients seem to live longer than ... Cancer , a peer-reviewed journal of the American Cancer ... types of cancer, certain yet-to-be-defined genetic and/or environmental factors ... studies that look at ethnic and racial disparities in ...
... Health (NIH) scientists and their colleagues in China have ... called sasX , which plays a pivotal role ... in most of Asia. Senior author Michael Otto, Ph.D., ... says these findings illustrate at the molecular level how ...
Cached Medicine News:Health News:Association for Psychological Science, SAGE launch Clinical Psychological Science 2Health News:Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder 2Health News:Stricter Seat Belt Laws Get Teens to Buckle Up, Study Shows 2Health News:Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology 2Health News:Hispanic lung cancer patients tend to live longer than blacks and whites 2Health News:NIH scientists link quickly spreading gene to Asian MRSA epidemic 2
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... OTEMR, Inc. , ONETOUCH EMR, 2.0 has achieved ONC ... the software is capable of supporting eligible providers with ... measures required to qualify for funding under the American ... certified on July 14, 2014 by ICSA Labs ... (ONC-ACB) and is compliant in accordance with applicable criteria ...
(Date:9/17/2014)... Sept. 17, 2014  Members of the physician ... Associates announced today that the enterprise is ... its image sharing capabilities and provide immediate cluster ... failures. In addition, the Dicom Systems enterprise imaging ... PACS systems to more effectively deliver the right ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... 4 NovaRx Corporation announced today the appointment of ... and Chief Operating Officer. Dr. Russell brings to ... discovery and a long history of success driving innovation ... experience leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... - Tasigna front-line data demonstrating potential in newly diagnosed patients with ... sessions at ASH , , - ... by significantly reducing toxic iron that can damage key organs , ... major independent breast cancer trial at SABCS to report on optimal ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
... water perfused manometric catheters for ... diagnostic tests. All Medtronic Water ... clear, medical grade PVC tubing. ... esophagus you will find a ...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
... Medtronic offers a family of single-use ... and convenience for you. This single-use catheter ... from the risk of infection and, because ... for patient care., ,We have water ...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
Medicine Products: